Inhale, exhale and predict
FORT LEE, N.J.—October saw Menssana Research Inc. report on the successful outcome for a clinical trial of its lung cancer prediction breath test. The first phase consisted of the analysis of breath samples from 301 patients screened for lung cancer with low-dose computerized tomography (LDCT) and lung biopsy. Menssana's research team discovered a lung cancer biomarker in the breath known as MAGIIC (mass abnormalities in gaseous ions with imaging correlates) via gas chromatography mass spectrometry. The second phase analyzed breath MAGIIC levels in 161 new participants without knowledge of their LDCT or biopsy results. The MAGIIC biomarker predicted biopsy-confirmed lung cancer with 84-percent accuracy and LDCT-confirmed lung nodules with 80.5-percent accuracy.
“There’s room to improve lung cancer screening because conventional screening with LDCT is expensive, generates many false positive findings, and subjects patients to a dose of radiation,” said Menssana CEO Dr. Michael Phillips, developer of the MAGIIC test.